A blockbuster drug is defined as one that reaches $1 billion in annual sales.
Below are the projected blockbusters and their projected 2023 sales:
1. Upadacitinib ($2.2 billion). The drug, manufactured by AbbVie, treats rheumatoid arthritis.
2. Zolgensma ($2.09 billion). The drug is manufactured by AveXiz and Novartis to treat spinal muscular atrophy.
3. Roxadustat ($1.97 billion). The drug treats anemia and is manufactured by AstraZeneca, FibroGen and Astellas.
4. Ultomiris ($1.93 billion). The drug treats Paroxysmal nocturnal hemoglobinuria, a rare blood disease that causes red blood cells to break apart. It is manufactured by Alexion.
5. Skyrizi ($1.74 billion). The drug treats psoriasis. It is manufactured by AbbVie and Boehringer Ingelheim.
6. AR101 ($1.17 billion). The biologic drug, manufactured by Aimmune, is designed to protect patients from severe allergic reactions if they are exposed to peanuts.
7. LentiGlobin ($1.12 billion). The drug, manufactured by Bluebird Bio, treats beta thalassemia, a blood disorder that reduces the production of hemoglobin.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.